Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy ParticipantsCompleted
NCT06948006Phase 1Updated Jul 23, 2025
Sponsor: AstraZeneca
Healthy Participants
United Kingdom
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.Completed
NCT06093542Phase 1Updated Jul 20, 2025
Sponsor: AstraZeneca
Heathy Participants
Japan
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy ParticipantsCompleted
NCT05107336Phase 1Updated Jul 20, 2025
Sponsor: AstraZeneca
Healthy Participants
Japan
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver DiseaseCompleted
NCT05560607Phase 1Updated Jul 20, 2025
Sponsor: AstraZeneca
Non-alcoholic Fatty Liver Disease · Fatty Liver, Nonalcoholic · NAFLD · Nonalcoholic Fatty Liver Disease
United States
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in RussiaCompleted
NCT05892926N/AUpdated Jul 20, 2025
Sponsor: AstraZeneca
Adenocarcinoma
Russia
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis BronchiectasisTerminated
NCT05006573Phase 3Updated Jul 20, 2025
Sponsor: AstraZeneca
Non-cystic Fibrosis Bronchiectasis
United States, Argentina, Australia, Canada, China +11 more
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.Terminated
NCT05864391Phase 1Updated Jul 20, 2025
Sponsor: AstraZeneca
Steatohepatitis
United States, Puerto Rico
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsCompleted
NCT05294458Phase 1Updated Jul 20, 2025
Sponsor: AstraZeneca
Non-alcoholic Steatohepatitis · Type 2 Diabetes Mellitus (T2DM) · Chronic Kidney Disease
United Kingdom
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)Terminated
NCT04125290N/AUpdated Jul 18, 2025
Sponsor: AstraZeneca
Hairy Cell Leukemia
United States
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After ChemoradiotherapyCompleted
NCT03798535N/AUpdated Jul 16, 2025
Sponsor: AstraZeneca
NSCLC
Australia, Belgium, France, Germany, Israel +5 more
Brilinta Clinical Experience InvestigationCompleted
NCT03212287N/AUpdated Jul 16, 2025
Sponsor: AstraZeneca
Acute Coronary Syndrome, Old Myocardial Infarction
Japan
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.Completed
NCT05408039N/AUpdated Jul 15, 2025
Sponsor: AstraZeneca
Hyperkalemia
United States, Germany, Italy, Spain, United Kingdom
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)Terminated
NCT05251909Phase 3Updated Jul 14, 2025
Sponsor: AstraZeneca
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
United States, Brazil, Italy, Japan, Netherlands +4 more
REported Outcomes in COPD With Trixeo in Real worlDCompleted
NCT05213611N/AUpdated Jul 11, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
United Kingdom
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompleted
NCT03534453Phase 3Updated Jul 10, 2025
Sponsor: AstraZeneca
Relapsed Ovarian Cancer · Following Complete or Partial Response to Platinum Based Chemotherapy · Platinum Sensitive
China, Malaysia
A Study in Participants With Non-cirrhotic NASH With FibrosisCompleted
NCT05638737Phase 2Updated Jul 9, 2025
Sponsor: AstraZeneca
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
United States, Argentina, Denmark, Italy, Mexico +4 more
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving SpironolactoneCompleted
NCT04676646Phase 4Updated Jul 9, 2025
Sponsor: AstraZeneca
Hyperkalaemia · Heart Failure With Reduced Ejection Fraction
United States, Brazil, Canada, Czechia, Hungary +3 more
BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair GenesTerminated
NCT03432897Phase 2Updated Jul 8, 2025
Sponsor: Brown University
Prostate Cancer · Adenocarcinoma of the Prostate
United States
US PRECISION Implementation StudyCompleted
NCT04891978NAUpdated Jul 8, 2025
Sponsor: AstraZeneca
Asthma
United States
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerActive Not Recruiting
NCT04062708Phase 2Updated Jul 8, 2025
Sponsor: Alliance Foundation Trials, LLC.
Stage IIIA Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
United States
A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462Completed
NCT06989983Phase 1Updated Jul 4, 2025
Sponsor: AstraZeneca
Heart Failure
United Kingdom
Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment StrategyActive Not Recruiting
NCT02284308N/AUpdated Jul 4, 2025
Sponsor: Maastricht Radiation Oncology
NSCLC
Netherlands
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart FailureActive Not Recruiting
NCT04789239Phase 2Updated Jul 4, 2025
Sponsor: Michael Fu
Heart Failure · Hyperkalemia
Sweden
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy ParticipantsCompleted
NCT06491550Phase 1Updated Jul 4, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC PatientsApproved For Marketing
NCT06279728N/AUpdated Jul 3, 2025
Sponsor: Daiichi Sankyo
EGFRm Advanced Non-Small Cell Lung Cancer · EGFRm Metastatic Non-Small Cell Lung Cancer
United States

Previous page Next page